Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Abstract

Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cancer cells. While ADCs like trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan have shown significant efficacy, resistance mechanisms such as antigen loss, impaired internalization, and efflux of cytotoxic payloads challenge their effectiveness. This review discusses these resistance mechanisms and explores advanced strategies to overcome them, including innovations in linker chemistry, multi-antigen targeting, and biomarker-driven personalization. Additionally, therapeutic sequencing - determining the optimal order of ADCs with other treatments such as chemotherapy, endocrine therapy, and immunotherapy - is examined as a crucial approach to maximize ADC efficacy and manage resistance. Evidence-based sequencing strategies, particularly for human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC), are supported by clinical trials demonstrating the benefits of ADCs in both early-stage and metastatic settings. The potential of combination therapies, such as ADCs with immune checkpoint inhibitors (ICIs), further highlights the evolving landscape of breast cancer treatment. As ADC technology advances, personalized approaches integrating biomarkers and optimized sequencing protocols offer promising avenues to enhance treatment outcomes and combat resistance in breast cancer.

Keywords

Antibody-drug conjugates / breast cancer / resistance mechanisms / therapeutic sequencing / combination therapy / targeted treatment

References

[1] Mark C,Cui X.Antibody-drug conjugates in breast cancer: current status and future directions.Int J Mol Sci2023;24:13726 PMCID:PMC10531043

[2] Ocaña A,Pandiella A.HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.Breast Cancer Res2020;22:15 PMCID:PMC6995165

[3] Loganzo F,Gerber HP.Mechanisms of resistance to antibody-drug conjugates.Mol Cancer Ther2016;15:2825-34

[4] Monteiro MR,Junior AADS.Antibody-drug conjugates in breast cancer: a comprehensive review of how to selectively deliver payloads.Breast Cancer2024;16:51-70 PMCID:PMC10909371

[5] Yamazaki CM,Anami Y.Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.Nat Commun2021;12:3528 PMCID:PMC8192907

[6] Najjar MK,Regua AT.Antibody-drug conjugates for the treatment of HER2-positive breast cancer.Genes2022;13:2065 PMCID:PMC9691220

[7] Cilliers C,Liao J,Thurber GM.Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy.AAPS J2016;18:1117-30 PMCID:PMC4996726

[8] Fenton MA,Graff SL.Sequencing antibody drug conjugates in breast cancer: exploring future roles.Curr Oncol2023;30:10211-23 PMCID:PMC10742750

[9] Li L,Lan B.Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: a Bayesian network meta-analysis.Cancer Innov2024;3:e126 PMCID:PMC11212280

[10] Gogia A,Desai C,Deshmukh C.Trastuzumab emtansine: antibody-drug conjugate in treatment of human epidermal growth factor receptor-2-positive metastatic breast cancer.Indian J Med Paediatr Oncol2018;39:79-87

[11] Dzimitrowicz H,Vargo C.T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.J Clin Oncol2016;34:3511-7 PMCID:PMC6075965

[12] You C,Chen Y.Evaluation of background parenchymal enhancement and histogram-based diffusion-weighted image in determining the molecular subtype of breast cancer.J Comput Assist Tomogr2021;45:711-6

[13] Linehan AS,Morris PG.Profile of trastuzumab deruxtecan in the management of patients with HER2-positive unresectable or metastatic breast cancer: an evidence-based review.Breast Cancer2021;13:151-9 PMCID:PMC7920506

[14] Wang J,Long F,Wang N.The expression and clinical significance of GADD45A in breast cancer patients.PeerJ2018;6:e5344 PMCID:PMC6098681

[15] Zimmerman BS.Next-generation HER2-targeted antibody-drug conjugates in breast cancer.Cancers2024;16:800 PMCID:PMC10887217

[16] Sharma U,Agarwal K.Potential of diffusion-weighted imaging in the characterization of malignant, benign, and healthy breast tissues and molecular subtypes of breast cancer.Front Oncol2016;6:126 PMCID:PMC4876309

[17] Vranic S.Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes.Biomol Biomed2023;23:189-90 PMCID:PMC10113938

[18] Damaskos C,Garmpi A.Evaluation of the histone deacetylase 2 (HDAC-2) expression in human breast cancer.Cancers2024;16:209 PMCID:PMC10777907

[19] Weddell J,Bhatnagar S,Shebley M.Mechanistic modeling of intra-tumor spatial distribution of antibody-drug conjugates: insights into dosing strategies in oncology.Clin Transl Sci2021;14:395-404 PMCID:PMC7877868

[20] Koukoutzeli C,Ascione L.Use of antibody-drug conjugates in the early setting of breast cancer.Clin Med Insights Oncol2024;18:11795549241260418 PMCID:PMC11185006

[21] Abelman RO,Spring LM,Bardia A.Mechanisms of resistance to antibody-drug conjugates.Cancers2023;15:1278 PMCID:PMC9954407

[22] Kwon MR,Ko ES.Correlation of shear-wave elastography stiffness and apparent diffusion coefficient values with tumor characteristics in breast cancer.Sci Rep2024;14:7180 PMCID:PMC10966029

[23] Chang HL,McArthur HL.Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.J Clin Invest2023;133:e172156 PMCID:PMC10503805

[24] Zhao P,Li W,Xiang G.Recent advances of antibody drug conjugates for clinical applications.Acta Pharm Sin B2020;10:1589-600 PMCID:PMC7564033

[25] Ríos-Luci C,Díaz-Rodríguez E.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity.Cancer Res2017;77:4639-51

[26] Yetkin Dİ,Durhan G.Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours.Pol J Radiol2021;86:e269-76 PMCID:PMC8186308

[27] Khongorzul P,Khan FU,Zhang J.Antibody-drug conjugates: a comprehensive review.Mol Cancer Res2020;18:3-19

[28] Kinneer K,Tiberghien AC.SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads.Clin Cancer Res2018;24:6570-82

[29] Li G,Shen BQ.Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells.Mol Cancer Ther2018;17:1441-53

[30] Wali VB,Pelekanou V.Identification and validation of a novel biologics target in triple negative breast cancer.Sci Rep2019;9:14934 PMCID:PMC6797726

[31] Criscitiello C,Curigliano G.Antibody-drug conjugates in solid tumors: a look into novel targets.J Hematol Oncol2021;14:20 PMCID:PMC7844898

[32] Tong JTW,Brimble MA.An insight into FDA approved antibody-drug conjugates for cancer therapy.Molecules2021;26:5847 PMCID:PMC8510272

[33] Watanabe T,Fujii T.Exo-cleavable linkers: a paradigm shift for enhanced stability and therapeutic efficacy in antibody-drug conjugates.J Med Chem2024;67:18124-38 PMCID:PMC11513888

[34] Gikanga B,Patapoff TW,Yi L.Cathepsin B cleavage of vcMMAE-based antibody-drug conjugate is not drug location or monoclonal antibody carrier specific.Bioconjug Chem2016;27:1040-9

[35] Phillips AC,Vaidya KS.ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope.Mol Cancer Ther2016;15:661-9

[36] Singh AP,Shah DK.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.J Pharmacokinet Pharmacodyn2016;43:567-82 PMCID:PMC5112145

[37] Ung M,Maio E.Breast cancer treatment and antibody drug conjugates: beyond T-DM1.Med Res Arch2021;9:

[38] Diamantis N.Antibody-drug conjugates--an emerging class of cancer treatment.Br J Cancer2016;114:362-7 PMCID:PMC4815767

[39] Okojie J,Barrott J.The future of antibody drug conjugation by comparing various methods of site-specific conjugation.Discov Med2023;35:921-7

[40] Peters S,Bubendorf L.Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers.Clin Cancer Res2019;25:64-72

[41] Abdollahpour-Alitappeh M,Gharibi T.Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes.J Cell Physiol2019;234:5628-42

[42] Jerjian TV,Thompson LA.Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy.Pharmacotherapy2016;36:99-116

[43] Ogitani Y,Hagihara K.DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.Clin Cancer Res2016;22:5097-108

[44] Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-41.

[45] Keskinkilic M.Antibody-drug conjugates in triple negative breast cancer.Clin Breast Cancer2024;24:163-74

[46] Khalid F,Singh V.Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: a systematic review.J Clin Oncol2022;40:e13068

[47] Rossi V,Rosato A.Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.Front Immunol2024;15:1447280 PMCID:PMC11357913

[48] Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20. PMCID:PMC10561652

[49] Yao P,Zhang S.Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis.Front Oncol2022;12:1039882 PMCID:PMC9850101

[50] Panikar SS,Shmuel S,Pereira PMR.In vivo biorthogonal antibody click for dual targeting and augmented efficacy in cancer treatment. bioRxiv 2023. PMCID:PMC10659283

[51] Conte P,Loibl S.Patient-reported outcomes from KATHERINE: a phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.Cancer2020;126:3132-9 PMCID:PMC7317721

[52] Li CL,Yi P.Bispecific antibodies, immune checkpoint inhibitors, and antibody-drug conjugates directing antitumor immune responses: challenges and prospects.Cell Biochem Funct2024;42:e70011

[53] Yin Y,Ouyang Q.Abstract OT1-03-02: efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study.Cancer Res2023;83:OT1-03

[54] Hamilton EP,Shastry M.A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).J Clin Oncol2023;41:1004

[55] Bardia A,Press MF.Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.Cancer Res2023;83:GS2-03

[56] Song H,Xie K.Crotonylation of MCM6 enhances chemotherapeutics sensitivity of breast cancer via inducing DNA replication stress.Cell Prolif2025;58:e13759 PMCID:PMC11839194

[57] Shao X,Chen Z.Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: a multicenter, randomized, phase II clinical trial.J Transl Int Med2024;12:466-77 PMCID:PMC11538898

[58] Saleh K,Khalife N.Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer.Cancer Drug Resist2024;7:22 PMCID:PMC11267152

[59] Zou Y,Chen B.crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer.Drug Resist Updat2024;77:101126

[60] García-Alonso S,Pandiella A.Resistance to antibody-drug conjugates.Cancer Res2018;78:2159-65

[61] Andreev J,Perez Bay AE.Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs.Mol Cancer Ther2017;16:681-93

[62] Guo Y,Zhao W.Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors.Adv Sci2024;11:e2306309 PMCID:PMC10987111

[63] Schumacher D,Leonhardt H.Current status: site-specific antibody drug conjugates.J Clin Immunol2016;36 Suppl 1:100-7 PMCID:PMC4891387

[64] Zeng Y,Dong Q.A traceless site-specific conjugation on native antibodies enables efficient one-step payload assembly.Angew Chem Int Ed Engl2022;61:e202204132

[65] Gong X,Ghosh SC.LGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence.Mol Cancer Ther2016;15:1580-90

[66] Cazzamalli S,Neri D.Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.J Control Release2017;246:39-45 PMCID:PMC5266555

[67] Yang B,Zhang J.Engineered drug delivery nanosystems for tumor microenvironment normalization therapy.Nano Today2023;49:101766

[68] Coënon L.From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement.Front Immunol2022;13:913215 PMCID:PMC9203678

[69] Yeap WH,Shimasaki N.CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.Sci Rep2016;6:34310 PMCID:PMC5037471

[70] Wang W,Hank JA,Sondel PM.NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.Front Immunol2015;6:368 PMCID:PMC4515552

[71] Chen YF,Shao ZM.Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.Cancer Commun2023;43:297-337 PMCID:PMC10009672

[72] Zhang J,Gao S.Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours.NPJ Breast Cancer2023;9:28 PMCID:PMC10113253

[73] Zhang L.Metabolic control of CD8⁺ T cell fate decisions and antitumor immunity.Trends Mol Med2018;24:30-48

[74] Belhabib I,Lac C,Jean C.Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy?.Cancers2021;13:3466 PMCID:PMC8303391

[75] Liu H,Liu H.The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.J Clin Oncol2024;42:e16614

[76] Wang J,Long F,Wang N.The expression and clinical significance of GADD45A in breast cancer patients.PeerJ2018;e5344 PMCID:PMC6098681

[77] Chang H,Low A.Abstract PO4-14-10: circulating tumor DNA as a biomarker for ADCs in metastatic breast cancer.Cancer Res2024;84:PO4-14

[78] Toledo B,Paniagua-Sancho M,Perán M.Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy.J Hematol Oncol2024;17:44 PMCID:PMC11167803

[79] Xie Q,Chen Y.Role of CD8⁺ T lymphocyte cells: interplay with stromal cells in tumor microenvironment.Acta Pharm Sin B2021;11:1365-78 PMCID:PMC8245853

[80] Tan X,Li K.A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells.MAbs2023;15:2220466 PMCID:PMC10269389

[81] Müller P,Theurich S.Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.Cancer Immunol Res2:741-55

[82] Jiang W,He W.Exhausted CD8⁺ T cells in the tumor immune microenvironment: new pathways to therapy.Front Immunol2020;11:622509 PMCID:PMC7902023

[83] Tsao L,Ragusa J.Abstract A059: uncovering bystander killing mechanisms of trastuzumab deruxtecan (T-DXd): effective extracellular payload release via cathepsin L in HER2-low breast cancer.Cancer Immunol Res2024;12:A059

[84] Rinnerthaler G,Greil R.HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer.Int J Mol Sci2019;20:1115 PMCID:PMC6429068

[85] Thomas SP,Suga JM.Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).J Clin Oncol2024;42:3140

[86] Skidmore L,Knudsen NA.ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers.Mol Cancer Ther2020;19:1833-43

[87] Agarwal S,McGowen K.Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.J Clin Invest2023;133:e162148 PMCID:PMC10645377

[88] Beck A,Debaene F.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Expert Rev Proteomics2016;13:157-83

[89] Andre F,Loi S.Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).J Clin Oncol2022;40:3025

[90] Xu B,Fan Y.Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study.J Clin Oncol2024;42:104 PMCID:PMC11210948

[91] Hamilton EP,Shastry M. A phase 2 study of HER3-DXd in patients (Pts) with metastatic breast cancer (MBC). 2023. Available from: https://www.asco.org/abstracts-presentations/ABSTRACT412400. [Last accessed on 3 Mar 2025]

[92] Liu J,Li Y,Wu J.PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy.Front Pharmacol2021;12:731798

[93] Xia L,Qin Y.HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.Cell Chem Biol2021;28:610-24.e5 PMCID:PMC8141015

[94] Zhang L,Gao Y.Antibody-drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis.Sci Rep2024;14:22357 PMCID:PMC11436769

[95] He L,Wang Z.Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy.J Med Chem2021;64:15716-26

[96] Gedik ME,Oberholtzer N.Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.Cancer Res2024;84:1475-90 PMCID:PMC11063689

[97] Nucera S,Martorana F,Genta S.Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer.Biomedicines2024;12:1491 PMCID:PMC11274676

[98] Pinto A,Giampaglia M.Synergizing immunotherapy and antibody-drug conjugates: new horizons in breast cancer therapy.Pharmaceutics2024;16:1146 PMCID:PMC11435286

[99] Li H,Yofe I.Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma.Cell2019;176:775-89.e18 PMCID:PMC7253294

[100] Yu B.Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.J Hematol Oncol2019;12:94 PMCID:PMC6734251

[101] Wang Z,Gou L,Wang Y.Antibody-drug conjugates: recent advances in payloads.Acta Pharm Sin B2023;13:4025-59 PMCID:PMC10547921

[102] Hu A,Lin H,Yang H.Harnessing innate immune pathways for therapeutic advancement in cancer.Sig Transduct Target Ther2024;9:68

[103] Roussot N,Rébé C.Tumor immunogenic cell death as a mediator of intratumor CD8 T-cell recruitment.Cells2022;11:3672 PMCID:PMC9688834

[104] Schiavoni G,Gabriele L.Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response.Front Immunol2013;4:483 PMCID:PMC3872318

[105] Fu C.Dendritic cells and CD8 T cell immunity in tumor microenvironment.Front Immunol2018;9:3059 PMCID:PMC6306491

[106] Ahmed A.Targeting immunogenic cell death in cancer.Mol Oncol2020;14:2994-3006 PMCID:PMC7718954

[107] Òdena A,Brasó-Maristany F.Abstract P5-13-14: antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs).Cancer Res2022;82:P5-13

[108] Dakroub R,Hajj-Younes Y.Therapeutic advantage of targeting PRMT5 in combination with chemotherapies or EGFR/HER2 inhibitors in triple-negative breast cancers.Breast Cancer2023;15:785-99 PMCID:PMC10637385

[109] Shin SH,Park SS.An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers.Adv Sci2021;8:e2102414 PMCID:PMC8655175

[110] Lopez S,Bellone S.Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.Oncotarget2020;11:560-70 PMCID:PMC7007291

[111] Nicolò E,Boscolo Bielo L,Curigliano G.Antibody-drug conjugates in breast cancer: what is beyond HER2?.Cancer J2022;28:436-45

[112] Le Joncour V,Puhka M.A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine.Mol Cancer Ther2019;18:1721-30

[113] Saltalamacchia G,De Sanctis R.Charting the course in sequencing antibody-drug conjugates in breast cancer.Biomedicines2024;12:500 PMCID:PMC10967814

[114] Guidi L,Trapani D.Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances.Curr Opin Oncol2024;36:487-94

[115] Abdou Y,Abelman R.Abstract PO3-05-14: practice patterns for sequential use of antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer: results from a physician survey.Cancer Res2024;84:PO3-05

[116] Beck A,Dumontet C.Strategies and challenges for the next generation of antibody-drug conjugates.Nat Rev Drug Discov2017;16:315-37

[117] Hammood M,Leyton JV.Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-a necessity for future ADC research and development.Pharmaceuticals2021;14:674 PMCID:PMC8308841

[118] Barnscher SD,Yin K.Abstract 2052: screening novel format antibodies to design bispecific ADCs that address target heterogeneity.Cancer Res2024;84:2052

[119] Kendall RL,Johri S.Abstract 5797: next generation antibody drug conjugates: multi-payload conjugates targeting multiple mechanisms of cell killing.Cancer Res2024;84:5797

[120] Gao J,Lu Q.Single-cell RNA sequencing reveals cell subpopulations in the tumor microenvironment contributing to hepatocellular carcinoma.Front Cell Dev Biol2023;11:1194199 PMCID:PMC10272598